DISCLOSURES
Authors Vasile G, Ilyas M, Lazzara D, Jacobs D, and Matin T have no relevant conflicts of interest to disclose.
Eduardo Weiss MD is a speaker for Castle Biosciences, Inc.
Eduardo Weiss MD is a speaker for Castle Biosciences, Inc.
REFERENCES
1. Centers for Disease Control and Prevention. Melanoma Incidence and Mortality, United States–2012–2016. USCS Data Brief, no. 9. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2019.
2. SEER Data 2017.
3. Hsueh E et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol. 2017; 10:152. Doi 10.1186/s13045- 017-0520-1.
4. Greenhaw BN, Zitelli JA, Broadland DG. Estimation of prognosis in invasive cutaneous melanoma: an independent study of accuracy of gene expression profile test. Dermatol Surg. 2018; 44:1494-1500. Doi: 10.1097/ DSS. 0000000000001588.
5. Gastman BR et al. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. Head Neck. 2019; 41: 871-879. Doi: 10.1002/hed.25473.
6. Keller J et al. Prospective validation of the prognostic 41-gene expression profiling test in primary cutaneous melanoma. Cancer Med. 2019; 8: 2205- 2212. Doi: 10.1002/cam4.2128.
7. Podlipnik S et al. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study. JEADV. 2019; 33: 857-862. Doi: 10.1111/jdv.15454
2. SEER Data 2017.
3. Hsueh E et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol. 2017; 10:152. Doi 10.1186/s13045- 017-0520-1.
4. Greenhaw BN, Zitelli JA, Broadland DG. Estimation of prognosis in invasive cutaneous melanoma: an independent study of accuracy of gene expression profile test. Dermatol Surg. 2018; 44:1494-1500. Doi: 10.1097/ DSS. 0000000000001588.
5. Gastman BR et al. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. Head Neck. 2019; 41: 871-879. Doi: 10.1002/hed.25473.
6. Keller J et al. Prospective validation of the prognostic 41-gene expression profiling test in primary cutaneous melanoma. Cancer Med. 2019; 8: 2205- 2212. Doi: 10.1002/cam4.2128.
7. Podlipnik S et al. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study. JEADV. 2019; 33: 857-862. Doi: 10.1111/jdv.15454
AUTHOR CORRESPONDENCE
Gabriella Vasile DO gabriellava@pcom.edu
